Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Psychiatric Digital Biomarkers Market, by Type
1.4.2 Europe Psychiatric Digital Biomarkers Market, by Clinical Practice
1.4.3 Europe Psychiatric Digital Biomarkers Market, by End Use
1.4.4 Europe Psychiatric Digital Biomarkers Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Europe Psychiatric Digital Biomarkers Market by Type
4.1 Europe Wearable Market by Country
4.2 Europe Mobile based Applications Market by Country
4.3 Europe Sensors Market by Country
4.4 Europe Other Type Market by Country
Chapter 5. Europe Psychiatric Digital Biomarkers Market by Clinical Practice
5.1 Europe Diagnostic Psychiatric Digital Biomarkers Market by Country
5.2 Europe Monitoring Psychiatric Digital Biomarkers Market by Country
5.3 Europe Predictive and Prognostic Psychiatric Digital Biomarkers Market by Country
5.4 Europe Other Clinical Practice Market by Country
Chapter 6. Europe Psychiatric Digital Biomarkers Market by End Use
6.1 Europe Healthcare Companies Market by Country
6.2 Europe Healthcare Providers Market by Country
6.3 Europe Payers Market by Country
6.4 Europe Other End Use Market by Country
Chapter 7. Europe Psychiatric Digital Biomarkers Market by Country
7.1 Germany Psychiatric Digital Biomarkers Market
7.1.1 Germany Psychiatric Digital Biomarkers Market by Type
7.1.2 Germany Psychiatric Digital Biomarkers Market by Clinical Practice
7.1.3 Germany Psychiatric Digital Biomarkers Market by End Use
7.2 UK Psychiatric Digital Biomarkers Market
7.2.1 UK Psychiatric Digital Biomarkers Market by Type
7.2.2 UK Psychiatric Digital Biomarkers Market by Clinical Practice
7.2.3 UK Psychiatric Digital Biomarkers Market by End Use
7.3 France Psychiatric Digital Biomarkers Market
7.3.1 France Psychiatric Digital Biomarkers Market by Type
7.3.2 France Psychiatric Digital Biomarkers Market by Clinical Practice
7.3.3 France Psychiatric Digital Biomarkers Market by End Use
7.4 Russia Psychiatric Digital Biomarkers Market
7.4.1 Russia Psychiatric Digital Biomarkers Market by Type
7.4.2 Russia Psychiatric Digital Biomarkers Market by Clinical Practice
7.4.3 Russia Psychiatric Digital Biomarkers Market by End Use
7.5 Spain Psychiatric Digital Biomarkers Market
7.5.1 Spain Psychiatric Digital Biomarkers Market by Type
7.5.2 Spain Psychiatric Digital Biomarkers Market by Clinical Practice
7.5.3 Spain Psychiatric Digital Biomarkers Market by End Use
7.6 Italy Psychiatric Digital Biomarkers Market
7.6.1 Italy Psychiatric Digital Biomarkers Market by Type
7.6.2 Italy Psychiatric Digital Biomarkers Market by Clinical Practice
7.6.3 Italy Psychiatric Digital Biomarkers Market by End Use
7.7 Rest of Europe Psychiatric Digital Biomarkers Market
7.7.1 Rest of Europe Psychiatric Digital Biomarkers Market by Type
7.7.2 Rest of Europe Psychiatric Digital Biomarkers Market by Clinical Practice
7.7.3 Rest of Europe Psychiatric Digital Biomarkers Market by End Use
Chapter 8. Company Profiles
8.1 Canary Speech, Inc.
8.1.1 Company Overview
8.1.2 SWOT Analysis
8.2 Sonde Health, Inc. (Puretech Health Plc)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.4.2 Product Launches and Product Expansions:
8.2.5 SWOT Analysis
8.3 Koneksa Health Inc.
8.3.1 Company Overview
8.4 Empatica Inc.
8.4.1 Company Overview
8.5 VivoSense, Inc.
8.5.1 Company Overview
8.6 IXICO plc
8.6.1 Company Overview
8.7 Neurotrack Technologies, Inc.
8.7.1 Company Overview
8.8 WinterLight Labs
8.8.1 Company Overview
8.9 Aural Analytics, Inc. (Linus Health)
8.9.1 Company Overview
Unique Offerings 